- Home
- CRSR vs FBRX Comparison
CRSR vs FBRX Comparison
Compare CRSR & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRSR | FBRX |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 899.4M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CRSR | FBRX |
|---|---|---|
| Price | $9.44 | $44.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $8.50 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 1.8M | 824.3K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.37 | 61.30 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,472,480,000.00 | $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | $88.18 | ★ N/A |
| Revenue Growth | ★ 11.86 | N/A |
| 52 Week Low | $4.48 | $9.23 |
| 52 Week High | $13.10 | $45.36 |
Technical Indicators
Market Signals| Indicator | CRSR | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 83.89 |
| Support Level | $8.18 | $24.72 |
| Resistance Level | $9.69 | N/A |
| Average True Range (ATR) | 0.57 | 3.87 |
| MACD | 0.03 | 2.90 |
| Stochastic Oscillator | 72.24 | 92.19 |
Price Performance
Historical ComparisonAbout CRSR Corsair Gaming Inc.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the United States (U.S.), Americas (excluding U.S.) , Europe and the Middle East, and the Asia Pacific, of which maximum revenue is generated from United States (U.S.).
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.